Immunovant Posts $153M Q2 Loss, Eyes IMVT-1402 Data in H2 2026
IMVT has more than doubled off its 52-week low of $14.32.
Summary
Immunovant reported a $153.2M net loss for Q2 2026, with R&D spending of $142.6M as it advances IMVT-1402. Cash stands at $797.8M, providing runway into 2027. The company reiterated topline data for IMVT-1402 in difficult-to-treat rheumatoid arthritis and cutaneous lupus is expected in H2 2026, with registrational trials in Graves' disease and myasthenia gravis starting in 2027. The stock is up 54.5% year-to-date, trading near its 52-week high, reflecting optimism around the upcoming data readouts. This follows strong preliminary Phase 2b results in May that drove a significant rally.
At the time of this announcement, IMVT was trading at $39.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2B. The 52-week trading range was $14.32 to $41.23. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.